By Lisa Kerner
Charlotte, N.C., Aug. 15 - LipoScience, Inc. said it closed a $13 million round of series F financing.
"This funding will allow us to confidently invest in the deployment of our in-vitro diagnostic system and to continue to drive growth and awareness for the NMR LipoProfile test," president and chief executive officer Richard O. Braier said in a company news release.
The test measures the number of LDL particles, to determine risk for heart disease.
Participating in the financing round were Camden Partners, LLC; GE Capital Equity Investments; Invesco Private Capital; Pappas Ventures; Sightline Partners; Three Arch Partners and Varian, Inc.
LipoScience, based in Raleigh, N.C., develops and markets new clinical applications of NMR spectroscopy in the areas of cardiovascular disease and metabolic disorders.
| Issuer: | LipoScience Inc.
|
| Issue: | Series F financing
|
| Amount: | $13 million
|
| Investors: | Camden Partners, LLC; GE Capital Equity Investments; Invesco Private Capital; Pappas Ventures; Sightline Partners; Three Arch Partners and Varian, Inc.
|
| Announcement date: | Aug. 15
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
